lapatinib has been researched along with Carcinoma, Epidermoid in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (18.18) | 29.6817 |
| 2010's | 26 (78.79) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Butch, CJ; Li, Y; Shi, J; Wang, Y; Wang, Z; Xie, D; Zhu, YP | 1 |
| Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X | 1 |
| Feddersen, CR; Fletcher, EV; Goel, A; Koch, AT; Love-Homan, L; Simons, AL; Sobhakumari, A | 1 |
| Deeken, JF; He, AR; Hwang, J; Marshall, JL; Pishvaian, MJ; Ramos, C; Steadman, K; Subramaniam, D; Urso, CE; Wang, H; Wang, Y | 1 |
| Aburatani, H; Fukayama, M; Hoshino, H; Hosoya, Y; Ishikawa, S; Lefor, AK; Matsubara, D; Morishima, K; Niki, T; Saito, S; Sata, N; Ui, T; Yasuda, Y | 1 |
| Aderhold, C; Erben, P; Faber, A; Hoermann, K; Hofheinz, RD; Schultz, JD; Umbreit, C; Weiss, C; Wenzel, A | 1 |
| Datta, J; Lang, JC; Mapp, AK; Pan, Q; Piao, L; Teknos, TN; Xie, X; Zhang, M | 1 |
| Ahmed, N; Amonkar, M; Biswas-Baldwin, N; Bourhis, J; D'Cruz, A; D'Onofrio, I; Dietzsch, S; Dubinsky, P; El-Hariry, I; Ellis, C; Farrell, J; Franklin, N; Harrington, K; Holeckova, P; Horvath, Z; Jain, M; Legenne, P; Manikhas, G; Mehanna, H; Netherway, T; Santillana, S; Sun, Y; Temam, S; Wang-Silvanto, J; Wissel, P | 1 |
| Chan, KK; Furness, S; Glenny, AM; Wakeford, H; Weldon, JC; Worthington, HV | 1 |
| Mehra, R; Zibelman, M | 1 |
| Bagley, S; Bauml, J; Cohen, RB; Hayes, DN; Hwang, WT; Langer, C; Olson, JG; Weiss, JM | 1 |
| Kakudo, K; Nozaki, M; Ohnishi, Y; Yasui, H | 1 |
| Loeffler-Ragg, J; Schwentner, I; Sprinzl, GM; Zwierzina, H | 1 |
| Abidoye, O; Salgia, R; Sattler, M | 1 |
| Le, QT; Raben, D | 1 |
| Bourhis, J; D'Ambrosio, C; Deutsch, E; El-Hariry, IA; Harrington, KJ; Holford, CS; Lusinchi, A; Matthews, J; Nutting, CM; Pandeshwara, JS; Rosine, D; Tanay, M; Turner, SJ | 1 |
| Cohen, EE; Cooper, JB | 1 |
| Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R | 1 |
| Anderton, J; Barlaam, B; Beck, S; Callis, R; Davenport, S; Grosios, K; Hickinson, DM; Klinowska, T; Marshall, G; Mills, E; Ogilvie, D; Smith, P; Speake, G; Trigwell, C; Vincent, J; Wilkinson, RW | 1 |
| Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Takahashi, H; Toth, G; Tsukuda, M | 1 |
| Aisner, J; Allen, KE; Blumenschein, GR; Damjanov, N; Dowlati, A; Garst, J; Hassani, H; Leopold, L; Rigas, JR; Ross, HJ; Shepherd, FA; Smylie, M; Zaks, TZ | 1 |
| Breen, L; Clynes, M; Collins, DM; Dunne, G; O'Connor, R; Roche, S | 1 |
| Collins, DJ; del Campo, JM; DeSouza, NM; Diaz de Corcuera, I; El-Hariry, IA; Harrington, K; Koh, DM; Leach, MO; Orton, MR; Parera, M; Schmid, VJ; Whitcher, B | 1 |
| Biswas-Baldwin, N; Bourhis, J; Carracedo, C; Compton, N; Cupissol, D; De Raucourt, D; Del Campo, JM; Downie, L; El-Hariry, I; Harrington, KJ; Hitt, R; Lokanatha, D; Maroudias, N; Midwinter, D; Nutting, CM; Sebastian, P; Temam, S | 1 |
| Liebmann, C; Weisheit, S | 1 |
| Aktolga, S; Blair, EA; Bozeman, J; Cohen, EE; Dancey, JE; Davis, DW; de Souza, JA; Khattri, A; Kozloff, MF; Kunnavakkam, R; Lingen, MW; Nattam, S; Seiwert, TY; Stenson, KM; Vokes, EE; Wong, SJ; Zhang, Y | 1 |
| Bosch-Barrera, J; Brunet, J; Cufí, S; De Llorens, R; Martin-Castillo, B; Massaguer Vall-Llovera, A; Menendez, JA; Oliveras-Ferraros, C; Queralt, B; Salip, DC; Vazquez-Martin, A | 1 |
| Buechner, SA; Erne, P; Joshi, MB; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ | 1 |
| Boehm, A; Diet, A; Dietz, A; Mozet, C; Reiche, A; Schrader, C; Wichmann, G | 1 |
| Andry, G; Awada, A; Bogaerts, J; El-Hariry, I; Fortpied, C; Lacombe, D; Lalami, Y; Langendijk, JA; Liberatoscioli, C; Specenier, PM; Vermorken, JB | 1 |
| Albano, L; Balsari, A; Borrelli, S; Fabris, S; Magnifico, A; Mantovani, R; Neri, A; Ripamonti, F; Rossini, A; Tagliabue, E | 1 |
| Fujii, H; Jimmy So, A; Kono, K; Mimura, K; Shabbir, A; Yong, WP | 1 |
| Berrier, A; Biswas-Baldwin, N; Compton, N; de Mendoza, FH; El-Hariry, I; Fayette, J; Franklin, N; Harrington, K; Housset, M; Kumar, R; Lau, M; Legenne, P; Mehanna, H; Remenar, E; Robinson, M | 1 |
7 review(s) available for lapatinib and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; ErbB Receptors; Gefitinib; Humans; Immunotherapy; Lapatinib; Molecular Targeted Therapy; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2015 |
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus | 2016 |
EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Head and Neck Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
Integrating biologically targeted therapy in head and neck squamous cell carcinomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Lapatinib; Quinazolines | 2009 |
Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Signal Transduction; Treatment Outcome | 2009 |
Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Delivery Systems; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab | 2012 |
10 trial(s) available for lapatinib and Carcinoma, Epidermoid
| Article | Year |
|---|---|
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Female; Genetic Variation; Genotype; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2015 |
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Double-Blind Method; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; International Cooperation; Kaplan-Meier Estimate; Lapatinib; Maintenance Chemotherapy; Male; Middle Aged; Molecular Targeted Therapy; Odds Ratio; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bayes Theorem; Biomarkers; Carcinoma, Squamous Cell; Contrast Media; Endpoint Determination; Head and Neck Neoplasms; Humans; Lapatinib; Magnetic Resonance Imaging; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2011 |
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Disease Progression; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Squamous Cell; Placebos; Quinazolines; Single-Blind Method; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2011 |
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2012 |
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Induction Chemotherapy; Lapatinib; Laryngeal Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2012 |
Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Exanthema; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lapatinib; Male; Middle Aged; Neoplasm Staging; Papillomaviridae; Quinazolines; Radiotherapy Dosage; Treatment Outcome | 2013 |
16 other study(ies) available for lapatinib and Carcinoma, Epidermoid
| Article | Year |
|---|---|
A novel near-infrared EGFR targeting probe for metastatic lymph node imaging in preclinical mouse models.
Topics: Animals; Carcinoma, Squamous Cell; ErbB Receptors; Head and Neck Neoplasms; Humans; Lapatinib; Lymph Nodes; Mice; Mouth Neoplasms; Optical Imaging; Squamous Cell Carcinoma of Head and Neck | 2023 |
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Lapatinib; Male; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Quinazolines; Random Allocation; Receptor, ErbB-2; Transcriptome; Xenograft Model Antitumor Assays | 2013 |
EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Cytokines; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inflammation; Lapatinib; NADPH Oxidase 4; NADPH Oxidases; Oligonucleotide Array Sequence Analysis; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2013 |
The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Fibroblast Growth Factors; Fibroblasts; Hepatocyte Growth Factor; Humans; Lapatinib; Molecular Sequence Data; Paracrine Communication; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor | 2015 |
MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro.
Topics: Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Epigenesis, Genetic; ErbB Receptors; Gefitinib; Human papillomavirus 16; Humans; Lapatinib; Matrix Metalloproteinase 9; Quinazolines; Vimentin | 2015 |
miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.
Topics: Afatinib; Animals; Antineoplastic Agents; Base Sequence; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; ErbB Receptors; Gene Expression; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Lapatinib; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Proto-Oncogene Proteins c-ets; Quinazolines; RNA Interference; Signal Transduction; Transcription Factors; Tumor Burden | 2015 |
Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Cyclin D2; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Mouth Neoplasms; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2016 |
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Mice; Mice, Nude; Mice, SCID; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Lapatinib; Mice; Paclitaxel; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2010 |
Modulation of P-gp expression by lapatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Dimerization; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Immunoprecipitation; Lapatinib; Plasmids; Protein Conformation; Protein Kinase C-epsilon; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection | 2012 |
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Survival; Cetuximab; Drug Resistance, Neoplasm; Gene Amplification; Humans; Lapatinib; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Transcription, Genetic; Trastuzumab; Up-Regulation | 2012 |
T-Cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: impact on cell motility.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lapatinib; Membrane Microdomains; Quinazolines; rho GTP-Binding Proteins; Signal Transduction; Skin Neoplasms | 2012 |
Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Lapatinib; Quinazolines | 2012 |
EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Humans; Lapatinib; MCF-7 Cells; Neoplastic Stem Cells; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; STAT3 Transcription Factor | 2013 |